Biotech Stocks To Watch: SLS +160%, AYTU +48%, GLSI +32%, GLAS +24%
SELLAS Life Sciences (SLS) rose 160% after its cancer vaccine trial met primary endpoint, Aytu BioPharma (AYTU) gained 48% on a $56M acquisition deal, Glass House Brands (GLAS) advanced 24% on strong revenue and production, and Greenwich LifeSciences (GLSI) climbed 32% after breast cancer program abstracts were accepted for presentation.
How this was made
The 30-second read
Why it matters
Each named company has a distinct catalyst: SLS reports a Phase 3 primary endpoint win with quantified survival benefit and a planned FDA accelerated filing discussion; AYTU announces a cash acquisition with a per-share price and closing window; GLAS reports a major quarter-over-quarter revenue and production improvement with cost and EBITDA improvement; GLSI gets SABCS poster acceptance for its FLAMINGO-01 program.
Market read
The article provides catalyst-specific, tradable information for four biotech names, including a pivotal Phase 3 result, a defined M&A price, quarterly operating metrics, and a scheduled conference catalyst.
What to watch
For SLS, accelerated filing discussions are not approval yet; for AYTU, deal completion depends on regulatory and closing conditions; for GLSI, poster acceptance may not equal material new data.
Background
The piece is a multi-name biotech/healthcare roundup tied to clinical trial progress, an acquisition agreement, quarterly operating updates, and conference abstract acceptance.
Ticker impact
SELLAS shares surged about 160% after its Phase 3 REGAL trial met the primary overall survival endpoint and it plans FDA accelerated filing.
Likely continued upside pressure as traders price in accelerated filing discussions and higher odds of approval.
The article reports a primary endpoint win with quantified survival benefit and an explicit plan to discuss accelerated filing with the FDA and submit a BLA in 1H 2027.
Aytu jumped about 48% after agreeing to be acquired by Rosemont Pharmaceuticals for about $56 million in cash, with closing expected by end of 2026.
Likely support from deal arbitrage flows, with volatility tied to regulatory/closing risk until completion.
The article specifies the acquisition price per share, total deal value, and an expected closing timeframe, which are direct drivers of takeover pricing.
Glass House Brands rose about 24% after reporting sharply higher Q3 revenue, record biomass production, improved costs, and positive adjusted EBITDA.
Likely upward bias as investors focus on revenue acceleration, cost improvement, and the reiterated full-year production outlook.
The article provides multiple financial/production datapoints and a forecast reaffirmation, but it is not a discrete corporate action or regulatory catalyst.
Greenwich LifeSciences gained about 32% after two FLAMINGO-01 abstracts were accepted for poster presentation at SABCS on Dec. 9, 2026.
Likely modest upside or continued momentum into the conference as traders anticipate incremental trial readouts.
The acceptance is a tangible catalyst with a scheduled presentation date, but the article does not disclose new efficacy/safety results.
Market effects
Reinforces risk appetite for biotech catalysts, especially oncology Phase 3 outcomes and small-cap M&A activity.
Primarily US small/mid-cap biotech sentiment; limited direct cross-region linkage described.
Oncology and biotech conference calendar may influence global peer sentiment, but no direct global policy or supply shock is cited.
Counterpoint
Large single-day moves (especially SLS and AYTU) can overshoot; traders may fade strength if follow-on details, FDA feedback, or deal closing risks emerge.
Key entities
- companySELLAS Life Sciences Group, Inc.
Phase 3 REGAL trial met primary overall survival endpoint; plans accelerated filing discussion and BLA submission in 1H 2027.
- companyAytu BioPharma, Inc.
Agreed to be acquired by Rosemont Pharmaceuticals for about $56 million in cash; closing expected by end of 2026.
- companyGlass House Brands Inc.
Reported Q3 revenue growth, record biomass production, lower production costs, and positive adjusted EBITDA; reaffirmed full-year forecast.
- companyGreenwich LifeSciences, Inc.
Two FLAMINGO-01 abstracts accepted for SABCS poster presentation on Dec. 9, 2026.

